Jill DeSimone
Director/Board Member at PRAXIS PRECISION MEDICINES, INC.
Net worth: 45 846 $ as of 2024-05-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Robert Davis | M | 57 | 10 years | |
Dean Mitchell | M | 68 | 8 years | |
David Hale | M | 75 | 27 years | |
Richard Vincent | M | 61 | 7 years | |
Robert Iannone | M | 57 | 10 years | |
James Breitmeyer | M | 70 | 27 years | |
Michel Detheux | M | 57 | 12 years | |
Jak Knowles | M | - |
Affini-T Therapeutics, Inc.
Affini-T Therapeutics, Inc. BiotechnologyHealth Technology Affini-T Therapeutics, Inc. is a biotechnology company based in Watertown, MA. Affini-t is focused on developing potentially curative therapies for solid tumor cancers by unlocking the power of T cells and targeting core oncogenic drivers. The company's differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company is targeting Kras and other oncogenic and viral driver mutations to open a new and differentiated target space, thereby minimizing the risk of cancer. The company was founded by Jak Knowles and Arjun Goyal, with Jak Knowles serving as the CEO since incorporation. | 3 years |
Lauren Mastrocola | F | - | 5 years | |
Marcio Souza | M | 45 | 4 years | |
Tony Ho | M | 58 | 3 years | |
Jeffrey Chodakewitz | M | 68 | 3 years | |
Robert Wills | M | 70 | 5 years | |
Sandra Leung | F | 63 | 32 years | |
Mary Coe | F | 57 | 5 years | |
Kathy Yi | F | 52 |
Affini-T Therapeutics, Inc.
Affini-T Therapeutics, Inc. BiotechnologyHealth Technology Affini-T Therapeutics, Inc. is a biotechnology company based in Watertown, MA. Affini-t is focused on developing potentially curative therapies for solid tumor cancers by unlocking the power of T cells and targeting core oncogenic drivers. The company's differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company is targeting Kras and other oncogenic and viral driver mutations to open a new and differentiated target space, thereby minimizing the risk of cancer. The company was founded by Jak Knowles and Arjun Goyal, with Jak Knowles serving as the CEO since incorporation. | - |
Timothy Edwin Kelly | M | 51 | 3 years | |
Alex Nemiroff | M | 45 | 4 years | |
Aaron Davis | M | 45 | 4 years | |
Jennifer Zachary | F | 46 | 6 years | |
Xin Nakanishi | M | 62 | 6 years | |
Rajesh Krishnan | M | 51 | 5 years | |
Steven Petrou | M | - | 9 years | |
David Lee | M | 42 | 1 years | |
Amir Weiss | M | 47 | 12 years | |
Karl Hansen | M | - | 4 years | |
Kimberly McCutcheon Jablonski | F | - | 21 years | |
Chase Leavitt | M | 42 | 3 years | |
Arjun Goyal | M | - |
Affini-T Therapeutics, Inc.
Affini-T Therapeutics, Inc. BiotechnologyHealth Technology Affini-T Therapeutics, Inc. is a biotechnology company based in Watertown, MA. Affini-t is focused on developing potentially curative therapies for solid tumor cancers by unlocking the power of T cells and targeting core oncogenic drivers. The company's differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company is targeting Kras and other oncogenic and viral driver mutations to open a new and differentiated target space, thereby minimizing the risk of cancer. The company was founded by Jak Knowles and Arjun Goyal, with Jak Knowles serving as the CEO since incorporation. | 3 years |
Christine Seidman | M | 71 | 4 years | |
Paul Rothman | M | 65 | 9 years | |
Pamela Craig | F | 67 | 9 years | |
Inge Thulin | M | 69 | 6 years | |
Louis Schmukler | M | - | 13 years | |
William Young | M | 79 | 8 years | |
Dan Kisner | M | 77 | 5 years | |
Risa Lavizzo-Mourey | M | 69 | 4 years | |
Ann Rhoads | F | 58 | 4 years | |
Kathy Warden | F | 52 | 4 years | |
William LaRue | M | 73 | 7 years | |
Michael Carter | M | 86 | 5 years | |
Rosemary Mazanet | M | 68 | 3 years | |
David Hallal | M | 56 | 6 years | |
Charles Theuer | M | 60 | 6 years | |
Gregory Norden | M | 66 | 5 years | |
Merit Cudkowicz | M | 61 | 3 years | |
Tim van Hauwermeiren | M | 52 | 6 years | |
Stephen Mayo | M | 62 | 3 years | |
Alex Kane | M | - | 4 years | |
Jannie Oosthuizen | M | - | 3 years | |
Brooke Hinkson | F | - | 9 years | |
Andre Musto | M | - | 10 years | |
Carol Bowden | F | - | 10 years | |
Yvonne McGrath | M | 50 | 4 years | |
Michael Klobuchar | M | 48 | 3 years | |
Pablo Urbaneja | M | - | 3 years | |
Salim Yazji | M | 55 | 3 years | |
Yonatan Beker | M | - | 11 years | |
Dave Williams | M | 55 | 4 years | |
Dean Li | M | 62 | 7 years | |
Matthew Call | M | 51 | 5 years | |
Philippe Brantegem | M | - | 4 years | |
Matthew Gall | M | 47 | 4 years | |
Daniel Faga | M | 44 |
Affini-T Therapeutics, Inc.
Affini-T Therapeutics, Inc. BiotechnologyHealth Technology Affini-T Therapeutics, Inc. is a biotechnology company based in Watertown, MA. Affini-t is focused on developing potentially curative therapies for solid tumor cancers by unlocking the power of T cells and targeting core oncogenic drivers. The company's differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company is targeting Kras and other oncogenic and viral driver mutations to open a new and differentiated target space, thereby minimizing the risk of cancer. The company was founded by Jak Knowles and Arjun Goyal, with Jak Knowles serving as the CEO since incorporation. | 2 years |
Alyssa Wyant | F | 49 | 4 years | |
Peter Dannenbaum | M | - | 7 years | |
Eric Rubin | M | 65 | 6 years | |
Megan Sniecinski | F | 43 | 3 years | |
Michael Varney | M | 65 |
Affini-T Therapeutics, Inc.
Affini-T Therapeutics, Inc. BiotechnologyHealth Technology Affini-T Therapeutics, Inc. is a biotechnology company based in Watertown, MA. Affini-t is focused on developing potentially curative therapies for solid tumor cancers by unlocking the power of T cells and targeting core oncogenic drivers. The company's differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company is targeting Kras and other oncogenic and viral driver mutations to open a new and differentiated target space, thereby minimizing the risk of cancer. The company was founded by Jak Knowles and Arjun Goyal, with Jak Knowles serving as the CEO since incorporation. | 2 years |
Kelly McCue | F | - | 4 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Giovanni Caforio | M | 59 | 24 years | |
Yitzhak Peterburg | M | 73 | - | |
Lamberto Andreotti | M | 73 | 19 years | |
Mark Meltz | M | 50 | 4 years | |
Peter R. Dolan | M | 68 | 18 years | |
James Cornelius | M | 81 | 10 years | |
Charles A. Heimbold | M | - | 20 years | |
John E. Celentano | M | 64 | 31 years | |
Laurie Alsup | M | 70 | 15 years | |
Carlo de Notaristefani | M | 67 | 15 years | |
Nima Farzan | M | 48 | 4 years | |
Jeremy Levin | M | 70 | 6 years | |
Rochelle Lazarus | F | 76 | 16 years | |
Stefan Vitorovic | M | 39 | 4 years | |
Felicia Ladin | F | 52 | 6 years | |
Helen Sabzevari | M | 62 | 3 years | |
Laura Sepp-Lorenzino | M | 63 | 15 years | |
Michael Rome | M | 39 | 5 years | |
Iris Esther Beck Codner | F | 58 | - | |
Melissa Epperly | F | 46 | 4 years | |
Fouad Namouni | M | 55 | 21 years | |
Keith Flaherty | M | 53 | 5 years | |
William S. Marth | M | 69 | 2 years | |
Carl Gordon | M | 59 | 5 years | |
Charles Kidder | M | 79 | 12 years | |
James Robinson | M | 88 | 29 years | |
James Tananbaum | M | 60 | 4 years | |
Anthony Hooper | M | 69 | 15 years | |
Natarajan Sethuraman | M | 62 | 10 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 93 | 93.94% |
Israel | 8 | 8.08% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jill DeSimone
- Personal Network